T-cell Response Induced by the BNT162b2 COVID-19 Vaccine in Children.

ABSTRACT: Phase 1 and Phase 2/3 trials (NCT04816643) demonstrated that the mRNA-based coronavirus disease 2019 (COVID-19) vaccine BNT162b2 is tolerable and efficacious in (5-11-year-olds) following two 10 µg doses 21 days apart, and a third 10 µg dose after 6 months. Here, we show that vaccination induces neutralizing antibodies and T-cell immunogenicity in 10-11-year-old participants.

SUBMITTER: Vogler I 

PROVIDER: S-EPMC12680099 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature